TY - JOUR
T1 - Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants
AU - Parsi, Kurosh
AU - De Maeseneer, Marianne
AU - van Rij, Andre M.
AU - Rogan, Christopher
AU - Bonython, Wendy
AU - Devereux, John A.
AU - Lekich, Christopher K.
AU - Amos, Michael
AU - Bozkurt, Ahmet Kursat
AU - Connor, David E.
AU - Davies, Alun H.
AU - Gianesini, Sergio
AU - Gibson, Kathleen
AU - Gloviczki, Peter
AU - Grabs, Anthony
AU - Grillo, Lorena
AU - Hafner, Franz
AU - Huber, David
AU - Iafrati, Mark
AU - Jackson, Mark
AU - Jindal, Ravul
AU - Lim, Adrian
AU - Lurie, Fedor
AU - Marks, Lisa
AU - Raymond-Martimbeau, Pauline
AU - Paraskevas, Peter
AU - Ramelet, Albert Adrien
AU - Rial, Rodrigo
AU - Roberts, Stefania
AU - Simkin, Carlos
AU - Thibault, Paul K.
AU - Whiteley, Mark S.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7/24
Y1 - 2024/7/24
N2 - Background: Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity. Objectives: To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents. Methods: An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations. Results: Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended. Conclusion: Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.
AB - Background: Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity. Objectives: To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents. Methods: An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations. Results: Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended. Conclusion: Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85199868051&partnerID=8YFLogxK
U2 - 10.1177/02683555241260926
DO - 10.1177/02683555241260926
M3 - Article
C2 - 39046331
AN - SCOPUS:85199868051
SN - 0268-3555
VL - 39
SP - 683
EP - 719
JO - Phlebology
JF - Phlebology
IS - 10
ER -